Your browser doesn't support javascript.
loading
Predicting EGFR mutational status from pathology images using a real-world dataset.
Pao, James J; Biggs, Mikayla; Duncan, Daniel; Lin, Douglas I; Davis, Richard; Huang, Richard S P; Ferguson, Donna; Janovitz, Tyler; Hiemenz, Matthew C; Eddy, Nathanial R; Lehnert, Erik; Cabili, Moran N; Frampton, Garrett M; Hegde, Priti S; Albacker, Lee A.
Afiliação
  • Pao JJ; Foundation Medicine Inc., 150 Second Street, Cambridge, MA, USA.
  • Biggs M; Foundation Medicine Inc., 150 Second Street, Cambridge, MA, USA.
  • Duncan D; Foundation Medicine Inc., 150 Second Street, Cambridge, MA, USA.
  • Lin DI; Foundation Medicine Inc., 150 Second Street, Cambridge, MA, USA.
  • Davis R; Foundation Medicine Inc., 150 Second Street, Cambridge, MA, USA.
  • Huang RSP; Foundation Medicine Inc., 150 Second Street, Cambridge, MA, USA.
  • Ferguson D; Foundation Medicine Inc., 150 Second Street, Cambridge, MA, USA.
  • Janovitz T; Foundation Medicine Inc., 150 Second Street, Cambridge, MA, USA.
  • Hiemenz MC; Foundation Medicine Inc., 150 Second Street, Cambridge, MA, USA.
  • Eddy NR; Foundation Medicine Inc., 150 Second Street, Cambridge, MA, USA.
  • Lehnert E; Foundation Medicine Inc., 150 Second Street, Cambridge, MA, USA.
  • Cabili MN; Foundation Medicine Inc., 150 Second Street, Cambridge, MA, USA.
  • Frampton GM; Foundation Medicine Inc., 150 Second Street, Cambridge, MA, USA.
  • Hegde PS; Foundation Medicine Inc., 150 Second Street, Cambridge, MA, USA.
  • Albacker LA; Foundation Medicine Inc., 150 Second Street, Cambridge, MA, USA. lalbacker@foundationmedicine.com.
Sci Rep ; 13(1): 4404, 2023 03 16.
Article em En | MEDLINE | ID: mdl-36927889
ABSTRACT
Treatment of non-small cell lung cancer is increasingly biomarker driven with multiple genomic alterations, including those in the epidermal growth factor receptor (EGFR) gene, that benefit from targeted therapies. We developed a set of algorithms to assess EGFR status and morphology using a real-world advanced lung adenocarcinoma cohort of 2099 patients with hematoxylin and eosin (H&E) images exhibiting high morphological diversity and low tumor content relative to public datasets. The best performing EGFR algorithm was attention-based and achieved an area under the curve (AUC) of 0.870, a negative predictive value (NPV) of 0.954 and a positive predictive value (PPV) of 0.410 in a validation cohort reflecting the 15% prevalence of EGFR mutations in lung adenocarcinoma. The attention model outperformed a heuristic-based model focused exclusively on tumor regions, and we show that although the attention model also extracts signal primarily from tumor morphology, it extracts additional signal from non-tumor tissue regions. Further analysis of high-attention regions by pathologists showed associations of predicted EGFR negativity with solid growth patterns and higher peritumoral immune presence. This algorithm highlights the potential of deep learning tools to provide instantaneous rule-out screening for biomarker alterations and may help prioritize the use of scarce tissue for biomarker testing.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Adenocarcinoma de Pulmão / Neoplasias Pulmonares Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Adenocarcinoma de Pulmão / Neoplasias Pulmonares Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article